E Fund Management Co. Ltd. Cuts Stake in Natera, Inc. (NASDAQ:NTRA)

E Fund Management Co. Ltd. cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,260 shares of the medical research company’s stock after selling 177 shares during the period. E Fund Management Co. Ltd.’s holdings in Natera were worth $517,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. RiverPark Advisors LLC purchased a new position in shares of Natera in the fourth quarter worth $27,000. Oliver Lagore Vanvalin Investment Group increased its holdings in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Natera in the third quarter worth about $44,000. CWM LLC lifted its position in shares of Natera by 41.8% in the fourth quarter. CWM LLC now owns 1,867 shares of the medical research company’s stock worth $117,000 after buying an additional 550 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in Natera by 36.1% during the 4th quarter. First Horizon Advisors Inc. now owns 2,089 shares of the medical research company’s stock valued at $131,000 after buying an additional 554 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $93.97, for a total value of $175,348.02. Following the completion of the sale, the chief financial officer now directly owns 67,542 shares of the company’s stock, valued at $6,346,921.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Steven Leonard Chapman sold 9,326 shares of the business’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $88.36, for a total value of $824,045.36. Following the completion of the transaction, the chief executive officer now directly owns 246,957 shares of the company’s stock, valued at approximately $21,821,120.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $93.97, for a total value of $175,348.02. Following the sale, the chief financial officer now owns 67,542 shares of the company’s stock, valued at $6,346,921.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 380,750 shares of company stock valued at $31,864,820. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent research reports. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, May 1st. Piper Sandler upped their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Canaccord Genuity Group increased their price target on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 29th. The Goldman Sachs Group boosted their price objective on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Finally, Stephens reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Natera in a research note on Tuesday, January 30th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $86.40.

Natera Trading Down 1.5 %

Natera stock traded down $1.49 during trading hours on Wednesday, hitting $95.66. The company had a trading volume of 1,241,379 shares, compared to its average volume of 1,404,302. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10. The firm has a market cap of $11.55 billion, a P/E ratio of -25.24 and a beta of 1.38. The company has a 50-day moving average price of $91.82 and a two-hundred day moving average price of $70.64. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. On average, sell-side analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.